Business Description
Valeo Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA91915B1085
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | -1.96 | |||||
Debt-to-Equity | -1.11 | |||||
Debt-to-EBITDA | -4.98 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -6.5 | |||||
Beneish M-Score | -6.48 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 69.3 | |||||
3-Year EBITDA Growth Rate | -26.6 | |||||
3-Year EPS without NRI Growth Rate | -58.4 | |||||
3-Year FCF Growth Rate | -28.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 37.63 | |||||
9-Day RSI | 41.58 | |||||
14-Day RSI | 43.52 | |||||
6-1 Month Momentum % | -87.18 | |||||
12-1 Month Momentum % | -94.62 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.27 | |||||
Quick Ratio | 0.2 | |||||
Cash Ratio | 0.1 | |||||
Days Inventory | 74.86 | |||||
Days Sales Outstanding | 36.04 | |||||
Days Payable | 71.62 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.5 | |||||
Shareholder Yield % | -110.6 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 18.94 | |||||
Operating Margin % | -34.61 | |||||
Net Margin % | -60.18 | |||||
FCF Margin % | -17.08 | |||||
ROA % | -82.84 | |||||
ROIC % | -43.99 | |||||
3-Year ROIIC % | -67.67 | |||||
ROC (Joel Greenblatt) % | -475.41 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.08 | |||||
EV-to-EBIT | -4.03 | |||||
EV-to-EBITDA | -4.79 | |||||
EV-to-Revenue | 1.26 | |||||
EV-to-Forward-Revenue | 0.97 | |||||
EV-to-FCF | -7.47 | |||||
Earnings Yield (Greenblatt) % | -24.81 | |||||
FCF Yield % | -203.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Valeo Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 36.414 | ||
EPS (TTM) (€) | -0.233 | ||
Beta | 1.42 | ||
Volatility % | 153.53 | ||
14-Day RSI | 43.52 | ||
14-Day ATR (€) | 0.001212 | ||
20-Day SMA (€) | 0.005 | ||
12-1 Month Momentum % | -94.62 | ||
52-Week Range (€) | 0.0045 - 0.226 | ||
Shares Outstanding (Mil) | 98.66 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Valeo Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Valeo Pharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Valeo Pharma Inc Frequently Asked Questions
What is Valeo Pharma Inc(FRA:VP2)'s stock price today?
When is next earnings date of Valeo Pharma Inc(FRA:VP2)?
Does Valeo Pharma Inc(FRA:VP2) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |